Sorry!! The article you are trying to read is not available now.
Can Pfizer's New Drug Clip Abbott's Top-Selling Humira?
MINYANVILLE ORIGINAL As the world awaited results from the US presidential election Pfizer (NYSE:PFE) scored its own victory Tuesday with the approval of a pill that treats rheumatoid arthritis. With Xeljanz Pfizer is believed to have a potential blockbuster -- a drug that potentially generates a few billion dollars a year in revenue according to Wall Street analysts. Speculation by analysts also focuses on how much market share Pfizer can take from existing injected rheumatoid arthritis drugs including Amgen’s (NASDAQ:AMGN) Enbrel Johnson & Johnson’s (NYSE:JNJ) Remicade and the big gorilla Abbott Laboratories’ (NYSE:ABT) Humira. (Pfizer is unwinding a sales ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here